Eric Lefkofsky, Founder and CEO of Tempus, shared on LinkedIn:
”Congratulations to Moderna and Merck on today’s positive Phase 3 results for INTerpath-001, a major milestone for melanoma treatment and the future of more personalized care.
We are proud to partner with Moderna and Merck in support of this important program, sequencing patients as it advances, and we’re excited to see this work continue for the benefit of patients.”
Moderna and Merck Announce Positive Phase 3 INTerpath-001 Results in Melanoma
